Purespring on nephrology & gene therapy in kidney disease

Purespring Therapeutics is a precision nephrology company pioneering first-in-class, targeted genetic therapies designed to preserve kidney function. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Haseeb Ahmad, CEO of Purespring, who discusses transforming the treatment of kidney disease, an area of enormous unmet need, with more than 840 million people worldwide living with chronic kidney disease. Indeed, Purespring’s lead programme is the podocyte-targeted gene therapy PS-002, which is for IgA nephropathy (or IgAN). The conversation also touches upon the evolution of the gene therapy landscape more generally, and where next with this type of innovation in the nephrology space. You can listen to episode 267 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.